Holen Sie sich die Stockscreener-App
57.77
3.75%
-1.94
Handel nachbörslich:
57.77
Schlusskurs vom Vortag:
$59.71
Offen:
$60
24-Stunden-Volumen:
392.99K
Relative Volume:
0.64
Marktkapitalisierung:
$1.68B
Einnahmen:
$234.60M
Nettoeinkommen (Verlust:
$-13.23M
KGV:
-110.97
EPS:
-0.5206
Netto-Cashflow:
$19.61M
1W Leistung:
-3.85%
1M Leistung:
-2.40%
6M Leistung:
+36.31%
1J Leistung:
+181.15%
1-Tages-Spanne:
$57.08
$60.01
1-Wochen-Bereich:
$57.08
$62.18
52-Wochen-Spanne:
$17.11
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
57.77 | 1.74B | 234.60M | -13.23M | 19.61M | -0.5206 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
AnaptysBio (ANAB) may find a bottom soon, here's why you should buy the stock now - MSN
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $70 - Moomoo
Affiliate sale notice: ANAB (NASDAQ: ANAB) plans 10,000-share sale - Stock Titan
AnaptysBio Inc (ANAB) Stock Price, Quote, News & History - Benzinga
ANAB Technical Analysis | Trend, Signals & Chart Patterns | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
Wall Street analysts see a 38.75% upside in AnaptysBio (ANAB): Can the stock really move this high? - MSN
AnaptysBio (NASDAQ: ANAB) moves fiscal year-end to June 30, 2026 - Stock Titan
[144] ANAPTYSBIO, INC SEC Filing - Stock Titan
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year? - Yahoo Finance UK
ANAB Stock Price, Quote & Chart | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Dennis Mulroy (ANAB) files to sell 10,000 shares via option exercise - Stock Titan
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High? - Yahoo Finance
AnaptysBio (ANAB) Valuation After Spin Off And Shift To Royalty Focused Model - Sahm
AnaptysBio (NASDAQ:ANAB) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $90 - Moomoo
Point72 Group Holds 55,303 ANAB Shares (0.2%) — ANAB (ANAB) - Stock Titan
Sirenia Capital discloses 1.92M shares of AnaptysBio (NASDAQ: ANAB) - Stock Titan
Vanguard Group Inc. Increases Position in AnaptysBio, Inc. $ANAB - MarketBeat
Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway - TipRanks
AnaptysBio appoints Christopher Murphy as CFO - MSN
AnaptysBio: Daniel Faga Is Anticipated to Be the Initial CEO for Spin-Off >ANAB - Moomoo
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
HighMark Wealth Management LLC Has $4.56 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio (ANAB) director Owen Hughes receives 11,250 RSU equity grant - Stock Titan
AnaptysBio (NASDAQ: ANAB) director Hughes Owen files initial Form 3 insider report - Stock Titan
AnaptysBio (NASDAQ: ANAB) grants CFO 25,765 restricted stock units - Stock Titan
AnaptysBio (NASDAQ: ANAB) CFO Christopher Murphy files initial Form 3 - Stock Titan
ANAB Maintained by Barclays -- Price Target Raised to $75.00 - GuruFocus
ANAB Maintained by UBS -- Price Target Raised to $76.00 - GuruFocus
AnaptysBio Faces Pressure As Market Reacts to Update Today - Kalkine Media
UBS Adjusts Price Target on AnaptysBio to $76 From $70, Maintains Buy Rating - Moomoo
A Quick Look at Today's Ratings for AnaptysBio(ANAB.US), With a Forecast Between $75 to $93 - Moomoo
AnaptysBio (NASDAQ:ANAB) Trading Down 7.7% After Earnings Miss - MarketBeat
AnaptysBio stock rallies as Delaware court tosses Tesaro breach claim - MSN
AnaptysBio, Inc. Stock 12‑Month Price Target Raised to $70.54, Implies 8% Upside - TradingView
AnaptysBio, Inc. Stock 12‑Month Price Target Raised to $69.09, Implies 5% Upside - TradingView
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
AnaptysBio (ANAB) Swings Back To Q1 Loss Per Share Challenging Recent Profitability Hopes - Sahm
ANAB SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Anaptys (ANAB) Posts Strong Q1 Revenue Surpassing Expectations - GuruFocus
Nektar Therapeutics Raises $374 Million After Alopecia Data Release; AnaptysBio’s First Tracks Bio Debuts on NASDAQ - geneonline.com
Is AnaptysBio (ANAB) 51.9% Undervalued After Q1 2026 EPS/Revenue - GuruFocus
AnaptysBio (NASDAQ:ANAB) Releases Earnings Results, Misses Expectations By $1.20 EPS - MarketBeat
AnaptysBio, Inc. (ANAB) Misses Q1 EPS by 88c - StreetInsider
AnaptysBio Appoints New CFO and Board Director - The Globe and Mail
AnaptysBio (NASDAQ: ANAB) shifts to royalty focus after Q1 2026 loss - Stock Titan
AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings Flash (ANAB) AnaptysBio, Inc. Reports Q1 Revenue $25.6M, vs. FactSet Est of $18.9M - marketscreener.com
AnaptysBio (NASDAQ: ANAB) pivots to royalties and launches $100M buyback - Stock Titan
BRIEF-AnaptysBio Q1 Net Income USD -52.884 Million - TradingView
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):